Fig. 3: KRAS mutations and OS benefit of FTD/TPI versus placebo in the RECOURSE trial.
a, Kaplan–Meier curves of OS with FTD/TPI (red) or placebo (black) for patients with KRASG12 mutations (upper left panel), without KRASG12 mutations (upper right panel), with KRASG13 mutations (lower left panel) and without KRAS mutations (lower right panel). Censoring events are indicated by vertical bars on the corresponding curve. The dotted lines indicate the median OS. The table underneath each plot denotes the numbers at risk. Two-sided Wald test-based P values are shown. b, Forest plot of HRs for death and 95% CIs for patients treated with FTD/TPI versus placebo, subgrouped according to codon-specific KRAS mutation status. Two-sided Wald test-based P values for interaction (as calculated using Cox regression) indicate if the OS benefit of FTD/TPI treatment versus placebo was significantly different between subgroups, for which pairwise comparisons are indicated by the square brackets. aUnadjusted: stratified for two stratification factors of the trial (time from diagnosis of metastases (<18 versus ≥18 months) and region (Japan versus USA, Europe and Australia)). bAdjusted: adjusted by the two stratification factors used in unadjusted analysis plus eight additional baseline characteristics (Methods). Note that all Cox regression models passed the proportional-hazards assumption. NE, not estimated; OS, overall survival.
